Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Dr. Miguel-Angel Perales discusses the need to expand access to CAR T-cell therapy by increasing awareness among community physicians. Real-world data show comparable or improved outcomes compared to trials, even in older and sicker patients, underscoring the importance of timely referrals for this innovative cancer treatment.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Three experts discuss data presented at ASH 2024 on BCMA-targeting agents in multiple myeloma.
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
Three experts discuss data presented at COMy and EHA 2024 on BCMA-targeting agents in multiple myeloma.
The EHA 2024 congress has once again united top haematology experts from around the globe. This year's event featured plenty of innovations and developments, from novel therapies to cutting-edge genetic studies. In this article we provide an overview of the late-breaking abstracts presented at the meeting.
We’re looking forward to the EHA 2024 Hybrid Congress which is taking place in Madrid, between 13-16 June 2024. Promising attendees the opportunity to explore the latest advancements in haematology, including cutting-edge technologies, treatments, and products. The focus will encompass a ...
Learn about investigational protein degradation and immunomodulatory therapies in multiple myeloma.
Watch three specialists discuss patient cases and share their insights on optimization of treatment selection and sequencing in relapsed/refractory multiple myeloma (RRMM).
Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.